Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00872131 |
This study will attempt to identify gene and brain activity markers that predict whether people with social anxiety disorder will respond to selective serotonin reuptake inhibitor medications.
Condition | Intervention | Phase |
---|---|---|
Anxiety Disorders |
Drug: Sertraline |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Neuro-Genetic Markers of SSRI Treatment Response in Social Anxiety Disorder |
Estimated Enrollment: | 80 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | May 2011 |
Estimated Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
|
Drug: Sertraline
Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
|
2: No Intervention
Healthy control participants will undergo MRI scanning.
|
Social anxiety disorder (SAD) is an anxiety disorder characterized by excessive fear and avoidance of social situations. Selective serotonin reuptake inhibitors (SSRIs) are a medication commonly prescribed to treat social anxiety disorder, but as many as 50% of people with SAD do not respond to SSRIs.
Current theory suggests that neurological functioning and genetics may influence a patient's response to treatment. This study will examine variations in genetics and brain reactivity among people with SAD who do and do not respond to SSRIs. Through this, the study will identify neurological and genetic biomarkers that can predict responsiveness to SSRI treatment in people with SAD.
Participation in this study will last 14 weeks. Both healthy people and people with SAD will be recruited to participate. All participants will complete similar study visits at entry, within 2 weeks of entry, and 12 weeks after that. The first visit, which will occur at study entry, will include screening questionnaires, an interview with research staff, a medical screening, a urine test, and collection of saliva samples for genotyping. The second visit and the last visit, which will be separated by 12 weeks, will involve MRI scans and behavioral tasks to be conducted inside and outside the MRI scanner.
Over the 12 weeks between MRI scanning sessions, participants with SAD will take sertraline, a common SSRI, on a daily basis. They will also attend five additional visits during this time to complete assessments of their symptoms. These visits will occur 1, 2, 4, 8, and 12 weeks after starting sertraline treatment. Participants with SAD will therefore be completing a symptom assessment, MRI scans, and behavioral tasks all on the final visit, 12 weeks after the second visit.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
For social anxiety disorder group:
For healthy control group:
Exclusion Criteria:
Additional exclusion criteria for the functional MRI studies:
United States, Michigan | |
University of Michigan | Recruiting |
Ann Arbor, Michigan, United States, 48109 | |
Contact: K. Luan Phan, MD 734-936-9275 luan@med.umich.edu | |
Principal Investigator: K. Luan Phan, MD |
Principal Investigator: | K. Luan Phan, MD | University of Michigan |
Responsible Party: | University of Michigan ( K. Luan Phan ) |
Study ID Numbers: | K23 MH076198, DAHBR 9A-ASPI, 5K23MH076198 |
Study First Received: | March 30, 2009 |
Last Updated: | March 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00872131 History of Changes |
Health Authority: | United States: Federal Government |
Anxiety Social Phobia Generalized Social Anxiety Disorder |
Neurotransmitter Agents Anxiety Disorders Mental Disorders Psychotropic Drugs Sertraline |
Phobic Disorders Serotonin Uptake Inhibitors Serotonin Antidepressive Agents |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Phobic Disorders Serotonin Uptake Inhibitors Pharmacologic Actions |
Serotonin Agents Pathologic Processes Anxiety Disorders Mental Disorders Therapeutic Uses Sertraline Central Nervous System Agents Antidepressive Agents |